Humacyte(US:HUMA) GlobeNewswire News Room·2024-11-26 22:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal recourse [2][4]. Group 1: Legal Investigation and Claims - The law firm is looking into claims against Humacyte, reminding investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Humacyte and its executives made false or misleading statements regarding the company's compliance with manufacturing practices and the FDA's review process [4]. Group 2: Stock Price Impact - Following a press release on August 9, 2024, regarding delays in the FDA's review of Humacyte's Biologic License Application (BLA), the company's stock price fell by $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [5]. - On October 17, 2024, after the FDA released a Form 483 detailing violations at Humacyte's manufacturing facility, the stock price dropped by $0.95, or 16.35%, closing at $4.86 per share on the same day [6]. Group 3: Manufacturing Violations - The FDA's Form 483 indicated significant violations at Humacyte's Durham, North Carolina facility, including lack of microbial quality assurance and inadequate quality oversight [6]. Group 4: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Humacyte's conduct, including whistleblowers and former employees, to contact the firm [7].